Will Radioimmunotherapy survive?

Clinical Advances in Hematology and Oncology

Volumn 5, Issue 10, 2007, Pages 782-784

  Zelenetz, Andrew D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; IBRITUMOMAB TIUXETAN; LENALIDOMIDE; PREDNISONE; RITUXIMAB; TOSITUMOMAB I 131; VINCRISTINE;

5Q- SYNDROME; ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG TARGETING; HUMAN; MONOTHERAPY; MYELODYSPLASIA; NONHODGKIN LYMPHOMA; PATIENT REFERRAL; RADIOIMMUNOTHERAPY; REIMBURSEMENT; ECONOMICS; FORECASTING; METHODOLOGY; SECOND CANCER;

FORECASTING; HUMANS; LYMPHOMA, NON-HODGKIN; NEOPLASMS, SECOND PRIMARY; RADIOIMMUNOTHERAPY;

EID: 38749137015     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Bennett JM, Kaminski MS, Leonard JP, et al. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood. 2005;105:4576-4582.
2. Czuczman MS, Emmanouilides C, Darif M, et al. Treatment-related myelodys-plastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J. Clin Oncol. 2007;25:4285-4292.
3. Kaminski MS, Tuck M, Estes J, et al. 1311-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352:441-449.
4. Nabhan C, Peterson LA, Kent SA, et al. Secondary acute myelogenous leukemia with MLL gene rearrangement following radioimmunotherapy (RAIT) for non-Hodgkin's lymphoma. Leuk Lymphoma. 2002;43:2145-2149.
5. Press OW, Unger JM, Braziel RM, et al; Southwest Oncology Group. Phasc II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol. 2006;24:4143-4149.
6. Vose JM, Wahl RL, Salch M, et al. Multicenter phase II study of iodine- 131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low- grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2000; 18:1316-1323.